For patients with a specific, inherited form of amyotrophic lateral sclerosis (ALS), a diagnosis often comes with a brutal footnote: there are no approved therapies that target the root genetic cause [PR Newswire, Nov 2026]. This is the clinical void that Toronto’s Specific Biologics is aiming to fill, not with a palliative treatment, but with a one-time genetic edit intended to be delivered inside the body. The company’s recently closed $35 million Series A financing, led by Hatteras Venture Partners, is earmarked to advance its lead Dualase® therapeutic candidate into an adaptive Phase I/II clinical trial [PR Newswire, Nov 2026]. The bet is that its proprietary dual-cleaving nuclease can safely reach motor neurons and precisely collapse the toxic DNA repeat expansions responsible for C9ORF72-associated ALS.
The Dualase Wedge: Exploiting a Natural Repair Pathway
While CRISPR-Cas9 brought gene editing into the mainstream, delivering editors safely into specific tissues in a living patient remains a formidable hurdle. Specific Biologics’ technical wedge is its Dualase platform, a system spun out of research by Western University biochemistry professor David Edgell [PERPLEXITY SONAR PRO BRIEF, Nov 2026]. The editor is engineered to make two cuts in DNA, a design the company says encourages the cell’s own, high-fidelity repair pathways to take over, leading to predictable deletions or repairs [PERPLEXITY SONAR PRO BRIEF, Nov 2026]. For the repeat expansions seen in C9ORF72 ALS, the goal is a clean deletion of the toxic sequence.
The platform is also built for delivery. The company’s pipeline outlines programs using single adeno-associated virus (AAV) or all-RNA formulations encapsulated in lipid nanoparticles, aiming for efficient in vivo delivery to the central nervous system, lungs, and liver [Pipeline | Specific Biologics]. Early, disease-agnostic validation of the platform’s core mechanics was published in the preprint repository bioRxiv in April 2024 [bioRxiv, Apr 2024].
A Team Built for the Clinic
The company’s evolution from academic concept to clinical-stage contender is reflected in its team build-out. Scientific founder David Edgell, who developed the underlying technique, serves as chair [David Edgell - Western University | LinkedIn]. CEO Brent Stead, a PhD biochemist with an MBA, co-founded the company in 2021 [Western University Schulich Medicine & Dentistry, Nov 2025]. The recent Series A coincided with strategic senior hires, bringing on U.S.-based Canadian gene-editing veterans Brad Geddes as Chief Scientific Officer and Paul Alloway as a consultant to bolster the clinical push [The Globe and Mail / Canadian Press, Nov 2026][RocketReach].
The board adds seasoned biotech governance, chaired by Paul Hastings, the former CEO of QLT Inc., and includes serial entrepreneur Richard Glickman [PERPLEXITY SONAR PRO BRIEF, Nov 2026][Lumira Ventures]. This blend of deep academic IP and late-stage development experience appears tailored to navigate the coming clinical and regulatory complexities.
| Role | Name | Background |
|---|---|---|
| Co-Founder & CEO | Brent Stead | PhD in Biochemistry, MBA [Western University Schulich Medicine & Dentistry, Nov 2025] |
| Scientific Co-Founder & Chair | David Edgell | Professor of Biochemistry, Western University; inventor of Dualase technique [PERPLEXITY SONAR PRO BRIEF, Nov 2026] |
| Chief Scientific Officer | Brad Geddes | U.S.-based gene-editing veteran recruited in 2026 [RocketReach] |
| Board Chair | Paul Hastings | Former CEO of QLT Inc. [PERPLEXITY SONAR PRO BRIEF, Nov 2026] |
| Board Member | Richard Glickman | Serial biotech entrepreneur [Lumira Ventures] |
Funding a Path to Human Proof-of-Concept
Specific Biologics has assembled capital through a mix of venture financing and non-dilutive grants, a common strategy for capital-intensive biotech startups. Its recent $35 million Series A was oversubscribed and joined by a syndicate of life science specialists including Genesys Capital and the BDC Life Sciences Venture Fund [PR Newswire, Nov 2026]. The capital is explicitly allocated to take the lead ALS program through initial clinical biomarker proof-of-concept in the first cohort of its adaptive trial.
Earlier support came from foundational investors like Lumira Ventures and adMare BioInnovations and disease-focused organizations. The Cystic Fibrosis Foundation funded early work on an inhalable nanoparticle system for lung delivery, showcasing the platform’s potential beyond neurology [Western University Schulich Medicine & Dentistry, Nov 2025]. In March 2026, the company and Western University also secured a C$1.8 million grant from Genome Canada and Ontario Genomics to build a machine-learning platform aimed at accelerating therapeutic development [Cision / Newswire, Mar 2026].
The In Vivo Editing Landscape and Inherent Risks
The ambition is vast, but the path is lined with risks inherent to first-in-human gene editing. The primary challenge is demonstrating both safety and a clear biomarker signal in a progressive, fatal disease. While the Dualase mechanism is designed for precision, off-target editing effects in the human central nervous system remain a paramount concern for regulators. Furthermore, the competitive landscape for genetic medicine in ALS is intensifying, with several other modalities, including antisense oligonucleotides and other gene therapies, in various stages of development, though none are yet approved for the C9ORF72 form.
The company’s answer to these risks appears to be a deliberate, milestone-driven approach. The adaptive trial design allows for learning from early cohorts, and the focus on a clear genetic subset of ALS patients may make it easier to detect a signal. The recruitment of veterans like Geddes and the governance of Hastings suggest a focus on clinical and regulatory rigor from the outset.
What Success Looks Like for Patients
The disease in focus, C9ORF72-associated ALS, accounts for a significant portion of familial ALS cases and some sporadic ones. It is characterized by a hexanucleotide repeat expansion in the C9ORF72 gene, which leads to the production of toxic RNA and dipeptide repeat proteins, ultimately causing the degeneration of motor neurons. The standard of care today is largely supportive, focusing on symptom management, respiratory support, and nutritional care. Approved drugs for ALS, like riluzole and edaravone, may modestly slow progression but do not address the underlying genetic driver for this patient population.
For Specific Biologics, the next twelve months will be defined by activating clinical trial sites and dosing its first patients. Success in the initial cohort would be a clean safety profile and a measurable change in a biomarker linked to the toxic repeat expansion. That proof-of-concept would not only validate the Dualase platform but also ignite the pipeline for other genetic diseases of the CNS and beyond. In a field where hope is often measured in months of extended life, the company is betting on a more fundamental rewrite.
Sources
- [PR Newswire, Nov 2026] Specific Biologics Announces Oversubscribed US$35 Million Series A Financing to Advance Gene-Editing Therapy for ALS | https://www.morningstar.com/news/pr-newswire/20261102to86258/specific-biologics-announces-oversubscribed-us-35-million-series-a-financing-to-advance-gene-editing-therapy-for-als
- [PERPLEXITY SONAR PRO BRIEF, Nov 2026] Specific Biologics company brief
- [Western University Schulich Medicine & Dentistry, Nov 2025] Gene Editing’s Next Frontier | https://www.schulich.uwo.ca/rapport/2025/people/gene_editings_next_frontier.html
- [The Globe and Mail / Canadian Press, Nov 2026] Can gene editing stop ALS? Toronto’s Specific Biologics advances therapy that could help some with fatal disease | https://ca.headtopics.com/news/can-gene-editing-stop-als-toronto-s-specific-biologics-89457604
- [Pipeline | Specific Biologics] Company pipeline page
- [bioRxiv, Apr 2024] Preprint on Dualase platform mechanics
- [David Edgell - Western University | LinkedIn] Professional profile
- [RocketReach] Professional profile for Brad Geddes
- [Lumira Ventures] Profile of Richard Glickman | https://www.lumiraventures.com/
- [Cision / Newswire, Mar 2026] Genome Canada and Ontario Genomics Award Specific Biologics and Western University $1.8 Million Grant | https://www.newswire.ca/news/specific-biologics-inc./
- [BIOTECanada, Nov 2026] Press release on lack of approved therapies for C9ORF72 ALS